<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1506210790
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BAVENCIO
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AVELUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4438
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SERONO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SERONO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Europe BV
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Bavencio contains the active substance avelumab, a monoclonal antibody (a type of protein) that attaches to a specific target in the body called PD-L1.</p><p dir="ltr">&nbsp;</p><p dir="ltr">PD-L1 is found on the surface of certain tumour cells, and helps protect them from the immune system (the body&rsquo;s natural defences). Bavencio binds to PD-L1, and blocks this protective effect, allowing the immune system to attack the tumour cells.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Bavencio is used in adults to treat:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Merkel cell carcinoma (MCC)<strong>, a rare type of skin cancer</strong>, when it is metastatic (has spread to other parts of the body).</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urothelial carcinoma (UC), <strong>a cancer that originates in the urinary tract</strong>, when it is advanced or metastatic (has spread beyond the urinary bladder or to other parts of the body). Bavencio is used as maintenance treatment if the tumour has not grown after so called platinum-based chemotherapy as the first treatment.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal cell carcinoma (RCC)<strong>, a type of kidney cancer</strong>, when it is advanced (has spread beyond the kidney or to other parts of the body).</p><p dir="ltr">&nbsp;</p><p dir="ltr">For renal cell cancer, Bavencio is to be used in combination with axitinib.</p><p dir="ltr">&nbsp;</p><p dir="ltr">It is important that you also read the package leaflet for the medicine containing axitinib. If you have any questions about axitinib, ask your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not use Bavencio</strong></p><p dir="ltr">if you are allergic to avelumab or any of the<strong> </strong>other ingredients<strong> </strong>of this medicine (listed in section&nbsp;6).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Blood tests and weight checks</u><u>:</u></p><p dir="ltr">Your doctor will check your general health before and during treatment with Bavencio.</p><p dir="ltr">You will have blood tests during your treatment and your doctor will monitor your weight<strong> </strong>before and during treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Talk to your doctor before receiving Bavencio:</u></p><p dir="ltr">It may cause side effects (see section&nbsp;4). Please note that in some cases symptoms may be delayed and may develop after your last dose. If you suffer from any of these, you should <strong>seek urgent medical attention:</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infusion‑related reactions;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems due to inflammation of your lungs (pneumonitis);</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of your liver (hepatitis) or other liver problems;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of your intestines (colitis), diarrhoea (watery, loose or soft stools) or more bowel movements than usual;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of your pancreas (pancreatitis);</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of your heart (myocarditis);</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with your hormone producing glands (the thyroid, adrenal and pituitary glands) that may affect how these glands work;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Type&nbsp;1 diabetes, including acid in the blood produced from diabetes (diabetic ketoacidosis);</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with your kidneys;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of your muscles (myositis).</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you experience any of these symptoms when taking Bavencio <strong>do not </strong>try to treat them on your own with other medicines. Your doctor may</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; give you other medicines in order to prevent complications and reduce your symptoms,</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; withhold the next dose of Bavencio,</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or stop your treatment with Bavencio altogether.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Check with your doctor or nurse before you receive Bavencio if:</u></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an autoimmune disease (a condition where the body attacks its own cells);</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS);</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had chronic viral infection of the liver, including hepatitis&nbsp;B (HBV) or hepatitis&nbsp;C (HCV);</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you receive medicines to suppress your immune system;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had an organ transplant.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr">Bavencio has not been studied in children and adolescents below 18&nbsp;years of age.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Other medicines and Bavencio</strong></p><p dir="ltr">Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy</strong></p><p dir="ltr">Bavencio can cause harm to your unborn baby. If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">You must not use Bavencio if you are pregnant unless your doctor specifically recommends it.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you are a woman who could become pregnant, you must use effective contraceptives while you are being treated with Bavencio and for at least 1&nbsp;month after your last dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Breast‑feeding</strong></p><p dir="ltr">If you are breast‑feeding, tell your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Do not</strong> breast‑feed while receiving Bavencio and for at least 1&nbsp;month after your last dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">It is unknown if Bavencio passes into your breast milk. A risk to the breast‑fed child cannot be excluded.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr"><strong>Do not</strong> drive or use machines after you have received Bavencio if you are not feeling well enough. Tiredness is a very common side effect of Bavencio and can affect your ability to drive or to use machines.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Bavencio has a low sodium content</strong></p><p dir="ltr">Bavencio contains less than 1&nbsp;mmol sodium (23&nbsp;mg) in each dose and therefore is essentially sodium‑free.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">You will receive Bavencio in a hospital or clinic, under the supervision of an experienced doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>How much Bavencio you will receive</strong></p><p dir="ltr">The recommended dose of avelumab is 800&nbsp;mg every 2&nbsp;weeks. Your doctor will decide how many treatments you need.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>How you will receive Bavencio</strong></p><p dir="ltr">You will receive Bavencio as an infusion (a drip) into a vein (intravenously) over a period of 1&nbsp;hour. Bavencio will be added to an infusion bag containing a sodium chloride solution before use.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Before you receive Bavencio</strong></p><p dir="ltr">For at least the first 4&nbsp;treatments, you will receive paracetamol and an antihistamine before being given Bavencio, to help to prevent possible side effects related to the infusion. Depending on how your body responds to treatment, your doctor may decide to continue giving you these medicines before all of your Bavencio treatments.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you miss a dose of Bavencio</strong></p><p dir="ltr">It is very important for you to keep all your appointments to receive Bavencio. If you miss an appointment, ask your doctor when to schedule your next dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you stop receiving Bavencio</strong></p><p dir="ltr"><strong>Do not </strong>stop treatment with Bavencio unless you have discussed this with your doctor. Stopping your treatment may stop the effect of the medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them. Some side effects may happen weeks or months after your last dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Bavencio acts on your immune system and may cause inflammation in parts of your body (see section&nbsp;2). Inflammation may cause serious damage to your body and some inflammatory conditions may lead to death and need treatment or withdrawal of Bavencio.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Seek urgent medical attention if you experience inflammation in any part of your body</strong> or if you have any of the following signs or symptoms, or if they get worse.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of infusion‑related reactions such as <strong>shortness of breath or wheezing</strong>, <strong>chills or shaking</strong>, <strong>bumpy rash or skin wheals</strong>, <strong>flushing</strong>, <strong>low blood pressure (</strong>dizziness, fatigue, nausea) <strong>feve</strong>r, <strong>back pain</strong>, and <strong>abdominal pain</strong>. This is very common.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of inflammation of hormone producing glands (which may affect how the glands work) may include <strong>extreme tiredness</strong>, <strong>rapid heartbeat</strong>, <strong>increased sweating</strong>, <strong>changes in mood or behaviour</strong>, such as irritability or forgetfulness, <strong>feeling cold</strong>, <strong>very low blood pressure (</strong>fainting, dizziness, fatigue, nausea), <strong>weight change</strong> or <strong>headache</strong>. This is very common for thyroid gland, common for adrenal glands, and uncommon for pituitary gland.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of inflammation of the lungs (pneumonitis) may be <strong>breathing difficulties</strong> or <strong>cough</strong>. This is common.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of inflammation of the intestines (colitis) may include <strong>diarrhoea</strong> (loose stools) or <strong>more bowel movements than usual</strong>, <strong>blood in your stools or dark, tarry, sticky stools</strong>, or <strong>severe stomach (abdomen) pain </strong>or <strong>tenderness</strong>. This is common.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of liver problems, including inflammation of the liver (hepatitis) may include <strong>yellowing of your skin</strong> (jaundice) or the <strong>whites of your eyes</strong>, <strong>severe nausea or vomiting</strong>, <strong>pain on the right side of your stomach area</strong> (abdomen), <strong>drowsiness</strong>, <strong>dark urine</strong> (tea coloured), <strong>bleeding or bruising more easily than normal</strong>, <strong>feeling less hungry than usual</strong>,<strong> tiredness</strong> or<strong> abnormal liver function tests</strong>. This is common.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of inflammation of the pancreas (pancreatitis) may include <strong>abdominal pain</strong>, <strong>nausea</strong> and <strong>vomiting</strong>. This is uncommon.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of inflammation of the heart (myocarditis) may include <strong>trouble breathing</strong>, <strong>dizziness</strong> or <strong>fainting</strong>, <strong>fever</strong>, <strong>chest pain</strong> and <strong>chest tightness</strong> or <strong>flu like symptoms</strong>. This is uncommon.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of type 1 diabetes may include <strong>feeling more hungry</strong> or <strong>thirsty than usual</strong>, <strong>needing to urinate more often</strong>, <strong>weight loss</strong>, and <strong>feeling tired</strong>. This is uncommon.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of inflammation of the kidney may include <strong>abnormal kidney function tests</strong>, <strong>urinating less than usual</strong>, <strong>blood in your urine</strong>, or <strong>swelling in your ankles</strong>. This is uncommon.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of inflammation of the muscles (myositis) may include <strong>muscle pain</strong> or <strong>weakness</strong>. This is uncommon.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Do not try to treat yourself with other medicines.</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Other side effects</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Some side effects may not have symptoms and may only be discovered through blood tests.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The following side effects have been reported in clinical trials with avelumab alone:</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Very common (may affect more than 1 in 10&nbsp;people)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the number of red blood cells</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, loose stools, constipation, vomiting</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Belly pain, back pain, joint pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough, shortness of breath</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling tired or weak</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling in the arms, feet or legs</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss, feeling less hungry</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Common (may affect up to 1 in 10&nbsp;people)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the number of a type of white blood cells (lymphocytes)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increases or decreases in blood pressure</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, dizziness</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling cold</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dryness in the mouth</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased pancreatic enzymes in the blood</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash, itching</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu‑like illness (includes feeling of fever, muscle aches)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness, tingling, weakness, burning sensation in arms or legs</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Uncommon (may affect up to 1 in 100&nbsp;people)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the number of platelets in the blood</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness in the skin</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bowel occlusion</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red, itchy, scaly patches on the skin</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammatory reaction of the whole body (Systemic inflammatory response syndrome)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the eye</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased liver enzymes in the blood</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in the number of a type of white blood cells (eosinophils)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased muscle enzyme in the blood</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guillain-Barr&eacute; Syndrome (an immune system disorder that causes nerve inflammation and can result in pain, numbness, muscle weakness and difficulty walking)</p><p dir="ltr">&nbsp;</p><p dir="ltr">The following side effects have been reported in clinical trials with avelumab in combination with axitinib:</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Very common (may affect more than 1 in 10&nbsp;people)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loose stools, nausea, constipation, vomiting</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increases in blood pressure</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling tired or weak</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hoarseness, cough, shortness of breath</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling less hungry, weight loss</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, dizziness</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain, back pain, belly pain, muscle pain</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased liver enzymes in the blood</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling cold</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash, itching</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Common (may affect up to 1 in 10&nbsp;people)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red, itchy, scaly patches on the skin, acne-like rash</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling in the arms, feet or legs</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dryness in the mouth</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased pancreatic enzymes in the blood</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased kidney function</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the number of red blood cells</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreases in blood pressure</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased glucose in the blood</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu‑like illness (includes feeling of fever, muscle aches)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased muscle enzyme in the blood</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the number of platelets in the blood</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness, tingling, weakness, burning sensation in arms or legs</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness in the skin</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Uncommon (may affect up to 1 in 100&nbsp;people)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in the number of a type of white blood cells (lymphocytes)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in the number of a type of white blood cells (eosinophils)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bowel occlusion</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. The expiry date refers to the last day of that month.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Store in a refrigerator (2&deg;C to 8&deg;C).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not freeze.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Store in the original package in order to protect from light.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not store any unused portion of the concentrate or of the diluted infusion solution for reuse.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Any unused medicine or waste material should be disposed of in accordance with local requirements.</p><p dir="ltr">&nbsp;</p><p dir="ltr">after preparation of infusion, store diluted BAVENCIO solution At room temperature up to 25&deg;C for no more than 4 hours from the time of dilution. Or, under refrigeration at 2&deg;C to 8&deg;C for no more than 24 hours from the time of dilution. If refrigerated, allow the diluted solution to come to room temperature prior to administration. Do not freeze or shake diluted solution&rdquo;.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Bavencio contains</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">The active substance is avelumab.</p><p dir="ltr">&nbsp;</p><p dir="ltr">One vial of 10&nbsp;mL contains 200&nbsp;mg of avelumab. Each mL of concentrate contains 20&nbsp;mg of avelumab.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The other ingredients are mannitol, glacial acetic acid, polysorbate&nbsp;20, sodium hydroxide, water for injections (see section&nbsp;2 &ldquo;Bavencio has a low sodium content&rdquo;).</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Bavencio looks like and contents of the pack
	Bavencio is a clear, colourless to slightly yellow concentrate for solution for infusion (sterile concentrate).
	
	The pack size is 1 glass vial per carton.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorisation Holder</strong></p><p dir="ltr">Merck Europe B.V.</p><p dir="ltr">Gustav Mahlerplein&nbsp;102</p><p dir="ltr">1082&nbsp;MA Amsterdam</p><p dir="ltr">The Netherlands</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Manufacturer</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">MERCK SERONO SA</p><p dir="ltr">Succursale d&rsquo;Aubonne</p><p dir="ltr">Zone Industrielle de l&rsquo;Ouriettaz</p><p dir="ltr">1170 Aubonne</p><p dir="ltr">Switzerland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in July 2021 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بافينسيو على مادة فعالة اسمها أفيلوماب، وهو جسم مضاد أحادي النسيلة (نوع من البروتين) يرتبط ببروتين محدد في الجسم اسمه PD-L1.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوجد بروتين PD-L1 على سطح خلايا ورم معين، ويساعد على حماية هذه الخلايا الورمية من جهاز المناعة (آلية الدفاع الطبيعية للجسم). ويرتبط بافينسيو ببروتين PD-L1، ويحجب هذا التأثير الوقائي، بما يسمح لجهاز المناعة بمهاجمة خلايا الورم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستعمل بافينسيو لعلاج البالغين المصابين بما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان خلية ميركل (MCC)، وهو <strong>نوع نادر من سرطان الجلد</strong>، من النوع النقيلي (أي انتشار السرطان إلى أجزاء أخرى من الجسم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الظهارة البولية (UC) ، وهو سرطان ينشأ في المسالك البولية ، عندما يكون متقدمًا أو منتشرًا (انتشر خارج المثانة البولية أو إلى أجزاء أخرى من الجسم). يستخدم Bavencio كعلاج وقائي إذا لم ينمو الورم بعد ما يسمى العلاج الكيميائي القائم على البلاتين كعلاج أول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الخلايا الكلوية (RCC)<strong>، نوع من سرطان الكلى</strong> عندما يكون متقدمًا (ينتشر خارج الكلى أو إلى أجزاء أخرى من الجسم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة الإصابة بسرطان الخلايا الكلوية، يُستعمل بافينسيو مع أكسيتينيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تقرأ أيضًا نشرة العبوة للأدوية التي تحتوي على أكسيتينيب. إذا كانت لديك أي أسئلة حول أكسيتينيب، فاسأل طبيبك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل بافينسيو</strong></p><p dir="RTL">إذا كانت لديك حساسية تجاه أفيلوماب أو أيٍ من المكونات الأخرى لهذا الدواء<strong> </strong>(المذكورة في القسم رقم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تحاليل الدم ومراجعة الوزن</u><u>:</u></p><p dir="RTL">سيراجع الطبيب حالتك الصحية العامة قبل العلاج بعقار بافينسيو وأثناء العلاج.</p><p dir="RTL">ستُجرى لك تحاليل دم خلال علاجك وسيتابع طبيبك وزنك<strong> </strong>قبل العلاج وأثنائه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>استشر طبيبك قبل تلقي العلاج باستخدام بافينسيو:</u></p><p dir="RTL">قد يسبب العقار آثارًا جانبية (انظر القسم رقم 4). يُرجى ملاحظة أنه في بعض الحالات، قد يتأخر ظهور الأعراض، وقد تظهر بعد جرعتك الأخيرة. إذا عانيت من أيٍ من الأعراض التالية، فينبغي لك أن <strong>تطلب الرعاية الطبية فورًا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات مرتبطة بالتسريب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهرت مشكلات مرتبطة بالتهاب رئتيك (الالتهاب الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في كبدك (التهاب الكبد) أو مشاكل الكبد الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أمعائك (التهاب القولون)، أو الإسهال (براز مائي أو رخو أو طري)، أو زيادة عدد مرات التبرز عن المعتاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في البنكرياس (التهاب البنكرياس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في القلب (التهاب عضلة القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الغدد المنتجة للهرمونات (الغدد الدرقية والكظرية والنخامية) التي قد تؤثر على طريقة عمل هذه الغدد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكري من النوع 1، بما في ذلك وجود حمض في الدم ناتج عن السكري (الحُماض الكيتوني السكري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في كليتيك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في عضلاتك (التهاب العضلات)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت من أيٍ من هذه الأعراض عند تلقي العلاج باستخدام بافينسيو، <strong>فلا</strong> تحاول علاجها بنفسك بتناول أدوية أخرى. فقد يرى طبيبك اتخاذ أي من الإجراءات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعطاؤك أدوية أخرى لمنع المضاعفات والتقليل من الأعراض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخير الجرعة التالية من بافينسيو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيقاف علاجك بعقار بافينسيو نهائيًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>راجع طبيبك أو ممرضتك قبل تلقي العلاج باستخدام بافينسيو إذا كان أيًا مما يلي ينطبق عليك:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المعاناة من أحد أمراض المناعة الذاتية (حالة يهاجم فيها الجسم خلاياه)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بعدوى فيروس نقص المناعة البشري (HIV) أو متلازمة نقص المناعة المكتسب (الإيدز)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق الإصابة بعدوى فيروسية مزمنة في الكبد، بما في ذلك التهاب الكبد بي (HBV) أو التهاب الكبد سي (HCV)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أدوية لتثبيط جهاز المناعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخضوع لعملية لزرع عضو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم تتم دراسة استخدام بافينسيو مع الأطفال والمراهقين الأقل من عمر 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بافينسيو والأدوية الأخرى</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أي أدوية أخرى أو تناولتها مؤخرًا أو ربما تتناولها في المستقبل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">قد يضر بافينسيو بجنينك. إذا كنتِ حاملاً، أو تعتقدين أنكِ حاملاً أو تخططين لإنجاب طفل، فاستشيري طبيبك قبل تلقي هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم استخدام بافينسيو أثناء الحمل ما لم يُوصِ طبيبك بالحصول عليه تحديدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ امرأة قادرة على الحمل، فيجب أن تستخدمي وسائل منع حمل فعالة أثناء علاجك بعقار بافينسيو ولمدة شهر واحد على الأقل بعد جرعتك الأخيرة منه.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">أخبري طبيبك إذا كنتِ ترضعين طفلك رضاعة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا </strong>ترضعي طفلك رضاعة طبيعية أثناء تلقيكِ بافينسيو ولمدة شهر واحد على الأقل بعد جرعتك الأخيرة منه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوافر معلومات عما إذا كان بافينسيو يصل إلى لبن الثدي أم لا. ولهذا لا يمكن استبعاد وجود خطر على الطفل الذي يرضع رضاعة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL"><strong>لا </strong>تقود السيارة أو تستعمل آلات بعد تلقيك تسريب بافينسيو ما لم تشعر أنك أصبحت على ما يرام. التعب أثر جانبي شائع جدًا لعقار بافينسيو وقد يؤثر على قدرتك على قيادة السيارة أو استعمال الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انخفاض محتوى بافينسيو من الصوديوم</strong></p><p dir="RTL">يحتوي بافينسيو على أقل من 1 مليمول من الصوديوم (23 ملغ) في كل جرعة ولهذا فإنه يكاد يكون خاليًا فعليًا من الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">ستحصل على بافينسيو في مستشفى أو عيادة، تحت إشراف طبيب خبير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جرعة بافينسيو التي ستحصل عليها</strong></p><p dir="RTL">الجرعة الموصى بها من أفيلوماب هي 800 ملغ كل أسبوعين. وسيحدد طبيبك عدد الجرعات التي ستحتاجها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف ستحصل على بافينسيو</strong></p><p dir="RTL">ستحصل على بافينسيو في صورة تسريب (تنقيط) في الوريد على مدار ساعة واحدة. ستتم إضافة بافينسيو إلى كيس تسريب يحتوي على محلول كلوريد صوديوم قبل الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل حصولك على بافينسيو</strong></p><p dir="RTL">في أول 4 جرعات على الأقل، ستحصل على باراسيتامول ومضاد هيستامين قبل إعطائك بافينسيو، وذلك للمساعدة في الوقاية من الآثار الجانبية المحتملة المرتبطة بالتسريب. وبناءً على استجابة جسمك للعلاج، قد يقرر طبيبك مواصلة إعطائك هذين الدوائين قبل كل جرعة من جرعات بافينسيو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا فاتتك جرعة من بافينسيو</strong></p><p dir="RTL">من المهم جدًا لك أن تحافظ على جميع مواعيدك للحصول على بافينسيو. إذا فاتك موعدًا، فاسأل طبيبك عن موعد جرعتك التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أوقفت تلقي بافينسيو</strong></p><p dir="RTL"><strong>لا </strong>توقف العلاج بدواء بافينسيو إلا بعد مناقشة هذا مع طبيبك. يمكن أن يؤدي وقف علاجك إلى وقف تأثير الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بخصوص استعمال هذا الدواء، فاسأل طبيبك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن كل الأدوية، يسبب هذا الدواء آثاراً جانبية على الرغم من أنها لا تصيب جميع من يتناوله. قد تحدث بعض الآثار الجانبية بعد أسابيع أو شهور من جرعتك الأخيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستهدف بافينسيو جهاز المناعة وقد يسبب التهابًا في أجزاء من الجسم (انظر القسم رقم 2). قد يسبب الالتهاب ضررًا خطيرًا بجسمك وقد تؤدي بعض حالات الالتهاب إلى الوفاة وتحتاج إلى العلاج أو سحب بافينسيو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اطلب الرعاية الطبية العاجلة إذا عانيت من التهاب في أي جزء من جسمك </strong>أو إذا ظهرت عليك، أو تفاقمت، أي من العلامات أو الأعراض التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>علامات لتفاعلات مرتبطة بالتسريب، مثل <strong>ضيق النفس أو أزيز عند التنفس</strong>، <strong>وقشعريرة أو رجفة</strong>، <strong>وطفح جلدي بارز، أو بثرات أ</strong>و هبات ساخنة<strong>،</strong><strong> </strong><strong>وانخفاض ضغط الدم (</strong>دُوار، تعب، غثيان) <strong>وحمى </strong>وألم بالظهر <strong>وألم بالبطن</strong>. وهذه الأعراض شائعة جدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>قد تشمل علامات التهاب الغدد المنتجة للهرمونات (والتي قد تؤثر على كيفية عمل الغدد) <strong>تعب شديد</strong>، أو <strong>سرعة ضربات القلب</strong>، <strong>أو زيادة التعرق</strong>، <strong>أو تغيرات في المزاج أو السلوك</strong>، مثل سرعة الانفعال أو النسيان، أو <strong>الإحساس بالبرودة</strong>، <strong>أو الانخفاض الشديد في ضغط الدم</strong> (إغماء، دُوار، تعب، غثيان)، أو <strong>تغير في الوزن</strong>، أو <strong>صداع</strong>. وهي علامات شائعة جدًا في الغدة الدرقية، وشائعة في الغدد الكظرية، وغير شائعة في الغدة النخامية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشمل علامات التهاب الرئة (الالتهاب الرئوي) <strong>صعوبة في التنفس</strong> أو <strong>سعال</strong>. وهذا أمر شائع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشمل علامات التهاب الأمعاء (التهاب القولون) <strong>الإسهال</strong> (البراز الرخو) أو <strong>التبرز أكثر من المعتاد</strong>، أو <strong>وجود دم في البراز أو إخراج براز داكن اللون أو في لون القطران أو لزج</strong>، أو <strong>ألم شديد بالمعدة</strong> (البطن) أو <strong>التعب</strong>. وهذا أمر شائع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشمل علامات مشكلات الكبد؛ بما في ذلك التهاب الكبد <strong>اصفرار الجلد</strong> (اليرقان) أو <strong>اصفرار بياض عينيك</strong>، أو<strong> الغثيان أو القيء الشديد،</strong> أو <strong>ألم في الجانب الأيمن من المعدة</strong> (البطن)، أو <strong>النعاس</strong>، أو <strong>بول داكن</strong> (بلون الشاي)، أو <strong>سهولة النزف أو ظهور الكدمات بسهولة أكثر من المعتاد</strong>، أو <strong>الإحساس بالجوع أقل من المعتاد</strong>، أو <strong>التعب</strong>، أو<strong> ظهور نتائج غير طبيعية باختبارات وظائف الكبد</strong>. وهذا أمر شائع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشمل علامات التهاب البنكرياس (التهاب البنكرياس) <strong>ألم في البطن</strong>، <strong>وغثيان، </strong>و<strong>قيء</strong>. وهذا أمر غير شائع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشمل علامات التهاب القلب (التهاب عضلة القلب) <strong>مشكلات في التنفس</strong>، أو <strong>دُوار</strong> أو <strong>إغماء</strong>، أو <strong>حمى</strong>، أو <strong>ألم في الصدر</strong> و<strong>ضيق في الصدر</strong> أو <strong>أعراض تشبه أعراض الإنفلونزا</strong>. وهذا أمر غير شائع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشمل علامات مرض السكري من النوع 1 <strong>الإحساس بجوع</strong> أو <strong>عطش أكثر من المعتاد</strong>، و<strong>الحاجة للتبول على فترات متقاربة</strong>، و<strong>فقدان الوزن</strong>، و<strong>الإحساس بالتعب</strong>. وهذا أمر غير شائع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشمل علامات التهاب الكلى <strong>نتائج غير عادية لاختبارات وظائف الكلى</strong>، أو <strong>التبول بوتيرة أقل من المعتاد</strong>، أو <strong>وجود دم في البول</strong>، أو <strong>تورم الكاحلين</strong>. وهذا أمر غير شائع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تشمل علامات التهاب العضلات <strong>ألم العضلات</strong> أو <strong>الضعف</strong>. وهذا أمر غير شائع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تحاول علاج نفسك بتناول أدوية أخرى.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">بعض الآثار الجانبية ليس لها أعراض وقد لا تُكتشف إلا من خلال اختبارات الدم فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن ظهور الآثار الجانبية التالية في تجارب سريرية اُستخدم فيها أفيلوماب فقط:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا (قد تصيب أكثر من </strong><strong>1</strong><strong> من كل </strong><strong>10</strong><strong> أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان، براز رخو، إمساك، قيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن، ألم بالظهر، ألم بالمفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال، ضيق في النفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالتعب أو الضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الذراعين أو القدمين أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن، أو قلة الإحساس بالجوع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشائعة (قد تصيب ما يصل إلى شخص واحد من كل </strong><strong>10</strong><strong> أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد نوع من خلايا الدم البيضاء (الخلايا اللمفاوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع أو انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، دُوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالبرد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات البنكرياس في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض شبيه بالأنفلونزا (يشمل الشعور بالحمى وآلام في العضلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر، وخز، وضعف، وشعور بالحرقة في الذراعين أو الساقين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير الشائعة (قد تصيب ما يصل إلى شخص واحد من كل </strong><strong>100</strong><strong> شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفيحات في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور بقع حمراء على الجلد بها قشور مع الرغبة في حكها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل التهابي للجسم كله (متلازمة الاستجابة الالتهابية الجهازية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات الكبد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة عدد نوع من خلايا الدم البيضاء (الحمضات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات العضلات في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة غيلان باريه (اضطراب في جهاز المناعة يسبب التهاب الأعصاب ويمكن أن ينتج عنه ألم وخدر وضعف في العضلات وصعوبة في المشي)</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن حدوث الآثار الجانبية التالية في تجارب سريرية اُستخدم فيها أفيلوماب مع أكسيتينيب:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا (قد تصيب أكثر من </strong><strong>1</strong><strong> من كل </strong><strong>10</strong><strong> أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز رخو، غثيان، إمساك، قيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالتعب أو الضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بحة، سعال، ضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الإحساس بالجوع، فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، دُوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل، ألم بالظهر، ألم بالبطن، ألم بالعضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات الكبد في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالبرد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشائعة (قد تصيب ما يصل إلى شخص واحد من كل </strong><strong>10</strong><strong> أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور بقع حمراء بها قشور وتثير الحكة على الجلد، طفح جلدي أشبه بحب الشباب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الذراعين أو القدمين أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات البنكرياس في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور وظائف الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الجلوكوز في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض شبيه بالأنفلونزا (يشمل الشعور بالحمى وآلام في العضلات)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات العضلات في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفيحات في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر، وخز، وضعف، وشعور بالحرقة في الذراعين أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير الشائعة (قد تصيب ما يصل إلى شخص واحد من كل </strong><strong>100</strong><strong> شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد نوع من خلايا الدم البيضاء (الخلايا اللمفاوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة عدد نوع من خلايا الدم البيضاء (الحمضات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن متناول الأطفال وأنظارهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا العقار بعد تاريخ انتهاء صلاحيته المدون على ملصق القنينة والعلبة بعد الاختصار EXP (انتهاء الصلاحية).</p><p dir="RTL">&nbsp;يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في الثلاجة (ما بين 2 و8 درجات مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحظر تجميده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ الدواء في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تحتفظ بأي مقدار غير مستخدم من المُركز أو محلول التسريب المخفف لإعادة استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد تحضير المحلول المخفف , قم بتخزين محلول BAVENCIO المخفف &nbsp;في درجة حرارة الغرفة حتى 25 درجة مئوية لمدة لا تزيد عن 4 ساعات من وقت التخفيف. أو ، تحت التبريد عند 2 درجة مئوية إلى 8 درجات مئوية لمدة لا تزيد عن 24 ساعة من وقت التخفيف. إذا تم تبريده ، اترك المحلول المخفف يصل إلى درجة حرارة الغرفة قبل الإستعمال. لا تجمده أو ترج المحلول المخفف &quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي التخلص من أي دواء غير مستخدم أو مخلفات وفقًا للاشتراطات المحلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات بافينسيو</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">المادة الفعالة هي أفيلوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي القنينة الواحدة حجم 10 مل على 200 ملغ من أفيلوماب. يحتوي كل مل من المُركز على 20 ملغ أفيلوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي مانيتول، حمض الخليك الثلجي، بوليسوربات 20، هيدروكسيد صوديوم، ماء للحقن (انظر القسم 2 &quot;انخفاض محتوى بافينسيو من الصوديوم&quot;).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل بافينسيو ومحتويات العبوة</strong></p><p dir="RTL">بافينسيو مُركز لإعداد محلول للتسريب، ويتراوح لونه ما بين الشفاف عديم اللون إلى الأصفر الفاتح (مُركز معقم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على قنينة زجاجية واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p dir="RTL">ميرك أوروبا B.V.</p><p dir="RTL">غوستاف ماهلر، 102</p><p dir="RTL">1082 MA أمستردام</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">ميرك سيرونو SA</p><p dir="RTL">فرع أوبون</p><p dir="RTL">منطقة أوريتاز الصناعية</p><p dir="RTL">1170 أوبون</p><p dir="RTL">سويسرا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذه النشرة كانت في يوليو 2021 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bavencio 20 mg/mL concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL of concentrate contains 20 mg of Avelumab.
One vial of 10 mL contains 200 mg of Avelumab.

Avelumab is a human monoclonal IgG1 antibody directed against the immunomodulatory cell surface ligand protein PD-L1 and produced in Chinese hamster ovary cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion (sterile concentrate).

Clear, colourless to slightly yellow solution. The solution pH is in the range of 5.0   5.6 and the osmolality is between 270 and 330 mOsm/kg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum‑based chemotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) (see section&nbsp;5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment should be initiated and supervised by a physician experienced in the treatment of cancer.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Posology</u></p><p dir="ltr">The recommended dose of Bavencio as monotherapy is 800&nbsp;mg administered intravenously over 60&nbsp;minutes every 2&nbsp;weeks.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Administration of Bavencio should continue according to the recommended schedule until disease progression or unacceptable toxicity.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The recommended dose of Bavencio in combination with axitinib is 800&nbsp;mg administered intravenously over 60&nbsp;minutes every 2&nbsp;weeks and axitinib 5&nbsp;mg orally taken twice daily (12&nbsp;hours apart) with or without food until disease progression or unacceptable toxicity.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For information on the posology of axitinib, please refer to the axitinib product information.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Premedication</u></em></p><p dir="ltr">Patients have to be premedicated with an antihistamine and with paracetamol prior to the first 4&nbsp;infusions of Bavencio. If the fourth infusion is completed without an infusion-related reaction, premedication for subsequent doses should be administered at the discretion of the physician.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Treatment modifications</u></em></p><p dir="ltr">Dose escalation or reduction is not recommended. Dosing delay or discontinuation may be required based on individual safety and tolerability; see Table&nbsp;1.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Detailed guidelines for the management of immune‑related adverse reactions are described in section&nbsp;4.4.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;</strong><strong>1: Guidelines for withholding or discontinuation of Bavencio</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:577px"><thead><tr><td style="vertical-align:top"><p><strong>Treatment-related adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Severity*</strong></p></td><td style="vertical-align:top"><p><strong>Treatment modification</strong></p></td></tr></thead><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Infusion‑related reactions</p></td><td style="vertical-align:top"><p>Grade&nbsp;1 infusion‑related reaction</p></td><td style="vertical-align:top"><p>Reduce infusion rate by 50%</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;2 infusion‑related reaction</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grade&nbsp;0‑1; restart infusion with a 50% slower rate</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3 or Grade&nbsp;4 infusion‑related reaction</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Pneumonitis</p></td><td style="vertical-align:top"><p>Grade&nbsp;2 pneumonitis</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grade&nbsp;0‑1</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3 or Grade&nbsp;4 pneumonitis or recurrent Grade&nbsp;2 pneumonitis</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatitis</p><p>&nbsp;</p><p>For Bavencio in combination with axitinib, see below.</p></td><td style="vertical-align:top"><p>Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 and up to 5&nbsp;times upper limit of normal (ULN) or total bilirubin greater than 1.5 and up to 3&nbsp;times ULN</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grade&nbsp;0‑1</p></td></tr><tr><td style="vertical-align:top"><p>AST or ALT greater than 5&nbsp;times ULN or total bilirubin greater than 3&nbsp;times ULN</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Colitis</p></td><td style="vertical-align:top"><p>Grade&nbsp;2 or Grade&nbsp;3 colitis or diarrhoea</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grade&nbsp;0‑1</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 colitis or diarrhoea or recurrent Grade&nbsp;3 colitis</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>Suspected pancreatitis</p></td><td style="vertical-align:top"><p>Withhold</p></td></tr><tr><td style="vertical-align:top"><p>Confirmed pancreatitis</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Myocarditis</p></td><td style="vertical-align:top"><p>Suspected myocarditis</p></td><td style="vertical-align:top"><p>Withhold</p></td></tr><tr><td style="vertical-align:top"><p>Confirmed myocarditis</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td style="vertical-align:top"><p>Endocrinopathies (hypothyroidism, hyperthyroidism, adrenal insufficiency, hyperglycaemia)</p></td><td style="vertical-align:top"><p>Grade&nbsp;3 or Grade&nbsp;4 endocrinopathies</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grade&nbsp;0‑1</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nephritis and renal dysfunction</p></td><td style="vertical-align:top"><p>Serum creatinine more than 1.5 and up to 6 times ULN</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grade&nbsp;0‑1</p></td></tr><tr><td style="vertical-align:top"><p>Serum creatinine more than 6&nbsp;times ULN</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Other immune-related adverse reactions (including myositis, hypopituitarism, uveitis, Guillain-Barr&eacute; syndrome)</p></td><td style="vertical-align:top"><p>For any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade&nbsp;2 or Grade&nbsp;3 clinical signs or symptoms of an immune-related adverse reaction not described above.</p></td><td style="vertical-align:top"><p>Withhold until adverse reactions recover to Grade&nbsp;0‑1</p></td></tr><tr><td style="vertical-align:top"><p>For any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Life threatening or Grade&nbsp;4 adverse reaction (excluding endocrinopathies controlled with hormone replacement therapy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrent Grade&nbsp;3 immune-related adverse reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Requirement for 10&nbsp;mg per day or greater prednisone or equivalent for more than 12&nbsp;weeks</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Persistent Grade&nbsp;2 or Grade&nbsp;3 immune-mediate adverse reactions lasting 12&nbsp;weeks or longer</p></td><td style="vertical-align:top"><p>Permanently discontinue</p></td></tr></tbody></table><p dir="ltr">* Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version&nbsp;4.0 (NCI‑CTCAE v4.03)</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Treatment modifications when Bavencio </em><em>is used in combination with axitin</em><em>ib</em></p><p dir="ltr">If ALT or AST &ge;&nbsp;3&nbsp;times ULN but &lt;&nbsp;5&nbsp;times ULN or total bilirubin &ge;&nbsp;1.5 times ULN but &lt;&nbsp;3 times ULN, both Bavencio and axitinib should be withheld until these adverse reactions recover to Grades&nbsp;0‑1. If persistent (greater than 5&nbsp;days), corticosteroid therapy with prednisone or equivalent followed by a taper should be considered. Rechallenge with Bavencio or axitinib or sequential rechallenge with both Bavencio and axitinib after recovery should be considered. Dose reduction according to the axitinib product information should be considered if rechallenging with axitinib.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If ALT or AST &ge;&nbsp;5&nbsp;times ULN or &gt;&nbsp;3&nbsp;times ULN with concurrent total bilirubin &ge;&nbsp;2&nbsp;times ULN or total bilirubin &ge;&nbsp;3 times ULN, both Bavencio and axitinib should be permanently discontinued and corticosteroid therapy should be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Dose modification advice for axitinib when used with Bavencio</em></p><p dir="ltr">When Bavencio is administered in combination with axitinib, please refer to the axitinib product information for recommended dose modifications for axitinib.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Special populations</u></em></p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr"><em>Elderly</em></p><p dir="ltr">No dose adjustment is needed for elderly patients (&ge;&nbsp;65&nbsp;years) (see sections&nbsp;5.1 and&nbsp;5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Paediatric population</em></p><p dir="ltr">The safety and efficacy of Bavencio in children and adolescents below 18&nbsp;years of age have not been established.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Renal impairment</em></p><p dir="ltr">No dose adjustment is needed for patients with mild or moderate renal impairment (see section&nbsp;5.2). There are insufficient data in patients with severe renal impairment for dosing recommendations.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Hepatic impairment</em></p><p dir="ltr">No dose adjustment is needed for patients with mild hepatic impairment (see section&nbsp;5.2). There are insufficient data in patients with moderate or severe hepatic impairment for dosing recommendations.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">Bavencio is for intravenous infusion only. It must not be administered as an intravenous push or bolus injection.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Bavencio has to be diluted with either sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection or with sodium chloride 4.5&nbsp;mg/mL (0.45%) solution for injection. It is administered over 60&nbsp;minutes as an intravenous infusion using a sterile, non‑pyrogenic, low‑protein binding 0.2&nbsp;micrometre in‑line or add‑on filter.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For instructions on the preparation and administration of the medicinal product, see section&nbsp;6.6.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Traceability</u></p><p dir="ltr">In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Infusion‑related reactions</u></p><p dir="ltr">Infusion‑related reactions, which might be severe, have been reported in patients receiving Avelumab (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be monitored for signs and symptoms of infusion‑related reactions including pyrexia, chills, flushing, hypotension, dyspnoea, wheezing, back pain, abdominal pain, and urticaria.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For Grade&nbsp;3 or Grade&nbsp;4 infusion‑related reactions, the infusion should be stopped and Avelumab should be permanently discontinued (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">For Grade&nbsp;1 infusion‑related reactions, the infusion rate should be slowed by 50% for the current infusion. For patients with Grade&nbsp;2 infusion‑related reactions, the infusion should be temporary discontinued until Grade&nbsp;1 or resolved, then the infusion will restart with a 50% slower infusion rate (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In case of recurrence of Grade&nbsp;1 or Grade&nbsp;2 infusion-related reaction, the patient may continue to receive Avelumab under close monitoring, after appropriate infusion rate modification and premedication with paracetamol and antihistamine (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In clinical trials, 98.6% (433/439) of patients with infusion-related reactions had a first infusion‑related reaction during the first 4&nbsp;infusions of which 2.7% (12/439) were Grade&nbsp;&ge;&nbsp;3. In the remaining 1.4% (6/439) of patients, infusion‑related reactions occurred after the first 4&nbsp;infusions and all were of Grade&nbsp;1 or Grade&nbsp;2.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Immune‑related adverse reactions</u></p><p dir="ltr">Most immune‑related adverse reactions with Avelumab were reversible and managed with temporary or permanent discontinuation of Avelumab, administration of corticosteroids and/or supportive care.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For suspected immune‑related adverse reactions, adequate evaluation should be performed to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction, Avelumab should be withheld and corticosteroids administered. If corticosteroids are used to treat an adverse reaction, a taper of at least 1-month duration should be initiated upon improvement.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients, whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants may be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune‑related pneumonitis</u></em></p><p dir="ltr">Immune‑related pneumonitis occurred in patients treated with Avelumab. One fatal case has been reported in patients receiving Avelumab (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be monitored for signs and symptoms of immune‑related pneumonitis and causes other than immune‑related pneumonitis should be ruled out. Suspected pneumonitis should be confirmed with radiographic imaging.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Corticosteroids should be administered for Grade&nbsp;&ge;&nbsp;2 events (initial dose of 1 to 2&nbsp;mg/kg/day prednisone or equivalent, followed by a corticosteroid taper).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab should be withheld for Grade&nbsp;2 immune‑related pneumonitis until resolution, and permanently discontinued for Grade&nbsp;3, Grade&nbsp;4 or recurrent Grade&nbsp;2 immune‑related pneumonitis (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune‑related hepatitis</u></em></p><p dir="ltr">Immune‑related hepatitis occurred in patients treated with Avelumab. Two fatal cases have been reported in patients receiving Avelumab (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be monitored for changes in liver function and symptoms of immune‑related hepatitis and causes other than immune‑related hepatitis should be ruled out.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Corticosteroids should be administered for Grade&nbsp;&ge;&nbsp;2 events (initial dose 1 to 2&nbsp;mg/kg/day prednisone or equivalent, followed by a corticosteroid taper).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab should be withheld for Grade&nbsp;2 immune‑related hepatitis until resolution and permanently discontinued for Grade&nbsp;3 or Grade&nbsp;4 immune‑related hepatitis (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune‑related colitis</u></em></p><p dir="ltr">Immune‑related colitis has been reported in patients receiving Avelumab (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be monitored for signs and symptoms of immune‑related colitis and causes other than immune‑related colitis should be ruled out. Corticosteroids should be administered for Grade&nbsp;&ge;&nbsp;2 events (initial dose of 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a corticosteroid taper).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab should be withheld for Grade&nbsp;2 or Grade&nbsp;3 immune‑related colitis until resolution, and permanently discontinued for Grade&nbsp;4 or recurrent Grade&nbsp;3 immune‑related colitis (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune‑related pancreatitis</u></em></p><p dir="ltr">Immune-related pancreatitis has been reported in patients receiving Avelumab. Two fatal cases have been reported in patients receiving Avelumab in combination with axitinib (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be monitored for signs and symptoms of immune‑related pancreatitis. In symptomatic patients, obtain gastroenterology consultation and laboratory investigations (including imaging) to ensure the initiation of appropriate measures at an early stage. Corticosteroids should be administered for immune‑related pancreatitis (initial dose of 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a corticosteroid taper).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab should be withheld in the event of suspected immune‑related pancreatitis. Avelumab should be permanently discontinued if immune‑related pancreatitis is confirmed (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune‑related myocarditis</u></em></p><p dir="ltr">Immune‑related myocarditis has been reported in patients receiving Avelumab. Two fatal cases have been reported in patients receiving Avelumab in combination with axitinib (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be monitored for signs and symptoms of immune‑related myocarditis. In symptomatic patients, obtain cardiologic consultation and laboratory investigations to ensure the initiation of appropriate measures at an early stage. Corticosteroids should be administered for immune‑related myocarditis (initial dose of 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a corticosteroid taper). If no improvement within 24&nbsp;hours on corticosteroids, additional immunosuppression (e.g., mycophenolate, infliximab, anti-thymocyte globulin) should be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab should be withheld in the event of suspected immune‑related myocarditis. Avelumab should be permanently discontinued if immune‑related myocarditis is confirmed (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune‑related endocrinopathies</u></em></p><p dir="ltr">Immune‑related thyroid disorders, immune‑related adrenal insufficiency, and Type&nbsp;1 diabetes mellitus have been reported in patients receiving Avelumab (see section&nbsp;4.8). Patients should be monitored for clinical signs and symptoms of endocrinopathies. Avelumab should be withheld for Grade&nbsp;3 or Grade&nbsp;4 endocrinopathies until resolution (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Thyroid disorders (hypothyroidism/hyperthyroidism</em><em>)</em></p><p dir="ltr">Thyroid disorders can occur at any time during treatment (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be monitored for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders. Hypothyroidism should be managed with replacement therapy and hyperthyroidism with anti‑thyroid medicinal product, as needed.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">Avelumab should be withheld for Grade&nbsp;3 or Grade&nbsp;4 thyroid disorders (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Adrenal insufficiency</em></p><p dir="ltr">Patients should be monitored for signs and symptoms of adrenal insufficiency during and after treatment. Corticosteroids should be administered (1&nbsp;to&nbsp;2&nbsp;mg/kg/day prednisone intravenously or oral equivalent) for Grade&nbsp;&ge;&nbsp;3 adrenal insufficiency followed by a taper until a dose of less than or equal to 10&nbsp;mg/day has been reached.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab should be withheld for Grade&nbsp;3 or Grade&nbsp;4 symptomatic adrenal insufficiency (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Type&nbsp;1 diabetes mellitus</em></p><p dir="ltr">Avelumab can cause Type&nbsp;1 diabetes mellitus, including diabetic ketoacidosis (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be monitored for hyperglycaemia or other signs and symptoms of diabetes. Initiate treatment with insulin for Type&nbsp;1 diabetes mellitus. Avelumab should be withheld and anti-hyperglycaemic in patients with Grade&nbsp;&ge;&nbsp;3 hyperglycaemia should be administered. Treatment with Avelumab should be resumed when metabolic control is achieved on insulin replacement therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune-related nephritis and renal dysfunction</u></em></p><p dir="ltr">Avelumab can cause immune-related nephritis (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be monitored for elevated serum creatinine prior to and periodically during treatment. Corticosteroids (initial dose of 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a corticosteroid taper) should be administered for Grade&nbsp;&ge;&nbsp;2 nephritis. Avelumab should be withheld for Grade&nbsp;2 or Grade&nbsp;3 nephritis until resolution to &le;&nbsp;Grade&nbsp;1 and permanently discontinued for Grade&nbsp;4 nephritis.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Other immune‑related adverse reactions</u></em></p><p dir="ltr">Other clinically important immune‑related adverse reactions were reported in less than 1% of patients: myositis, hypopituitarism, uveitis, and Guillain-Barr&eacute; syndrome (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">For suspected immune‑related adverse reactions, ensure adequate evaluation to confirm aetiology or to rule out other causes. Based on the severity of the adverse reaction, Avelumab should be withheld and corticosteroids to be administered. Avelumab should be resumed when the immune‑related adverse reaction returns to Grade&nbsp;1 or less following corticosteroid taper. Avelumab should be permanently discontinued for any Grade&nbsp;3 immune‑related adverse reaction that recurs and for Grade&nbsp;4 immune‑related adverse reaction (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Hepatotoxicity (in combination with axitinib)</u></em></p><p dir="ltr">Hepatotoxicity occurred in patients treated with Avelumab in combination with axitinib with higher than expected frequencies of Grade&nbsp;3 and Grade&nbsp;4 ALT and AST elevation compared to Avelumab alone (see section&nbsp;4.8).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be more frequently monitored for changes in liver function and symptoms as compared to when Avelumab is used as monotherapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab should be withheld for Grade&nbsp;2 hepatotoxicity until resolution and permanently discontinued for Grade&nbsp;3 or Grade&nbsp;4 hepatotoxicity. Corticosteroids should be considered for Grade&nbsp;&ge;&nbsp;2 events (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Patients excluded from clinical studies</u></p><p dir="ltr">Patients with the following conditions were excluded from clinical trials: active central nervous system (CNS) metastasis; active or a history of autoimmune disease; a history of other malignancies within the last 5&nbsp;years; organ transplant; conditions requiring therapeutic immune suppression or active infection with HIV, or hepatitis B or C.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Sodium content</u></p><p dir="ltr">This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, i.e. essentially &lsquo;sodium‑free&rsquo;.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No interaction studies have been conducted with Avelumab.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab is primarily metabolised through catabolic pathways, therefore, it is not expected that Avelumab will have pharmacokinetic drug‑drug interactions with other medicinal products.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Women of childbearing potential/Contraception</u></p><p dir="ltr">Women of childbearing potential should be advised to avoid becoming pregnant while receiving Avelumab and should use effective contraception during treatment with Avelumab and for at least 1&nbsp;month after the last dose of Avelumab.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">There are no or limited data from the use of Avelumab in pregnant women.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Animal reproduction studies have not been conducted with Avelumab. However, in murine models of pregnancy, blockade of PD‑L1 signalling has been shown to disrupt tolerance to the foetus and to result in an increased foetal loss (see section&nbsp;5.3). These results indicate a potential risk, based on its mechanism of action, that administration of Avelumab during pregnancy could cause foetal harm, including increased rates of abortion or stillbirth.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Human IgG1 immunoglobulins are known to cross the placental barrier. Therefore, Avelumab has the potential to be transmitted from the mother to the developing foetus. It is not recommended to use Avelumab during pregnancy unless the clinical condition of the woman requires treatment with Avelumab.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Breast‑feeding</u></p><p dir="ltr">It is unknown whether Avelumab is excreted in human milk. Since it is known that antibodies can be secreted in human milk, a risk to the new-borns/infants cannot be excluded.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Breast‑feeding women should be advised not to breast‑feed during treatment and for at least 1&nbsp;month after the last dose due to the potential for serious adverse reactions in breast‑fed infants.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">The effect of Avelumab on male and female fertility is unknown.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Although studies to evaluate the effect of Avelumab on fertility have not been conducted, there were no notable effects in the female reproductive organs in monkeys based on 1‑month and 3‑month repeat‑dose toxicity studies (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Avelumab has negligible influence on the ability to drive and use machines. Fatigue has been reported following administration of Avelumab (see section&nbsp;4.8). Patients should be advised to use caution when driving or operating machinery until they are certain that Avelumab does not adversely affect them.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Avelumab is most frequently associated with immune‑related adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of Avelumab (see &ldquo;Description of selected adverse reactions&rdquo; below).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Merkel cell carcinoma</u></em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">The safety of avelumab as monotherapy has been evaluated in 1,738&nbsp;patients with solid tumours including metastatic MCC receiving 10&nbsp;mg/kg every 2&nbsp;weeks of Avelumab in clinical studies. In this patient population, the most common adverse reactions with avelumab were fatigue (32.4%), nausea (25.1%), diarrhoea (18.9%), decreased appetite (18.4%), constipation (18.4%), infusion-related reactions (17.1%), weight decreased (16.6%), and vomiting (16.2%).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The most common Grade&nbsp;&ge;&nbsp;3 adverse reactions were anaemia (6.0%), dyspnoea (3.9%), and abdominal pain (3.0%). Serious adverse reactions were immune‑related adverse reactions and infusion‑related reaction (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tabulated list of adverse reactions</u></p><p dir="ltr">Adverse reactions reported for 88&nbsp;patients with metastatic MCC and for 1,650&nbsp;patients in a phase&nbsp;I study in solid tumours are presented in Table&nbsp;2. In both studies, avelumab was administered at 10&nbsp;mg/kg every 2&nbsp;weeks.</p><p dir="ltr">&nbsp;</p><p dir="ltr">These reactions are presented by system organ class and frequency. Frequencies are defined as: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;</strong><strong>2: Adverse reactions in patients treated with avelumab as monotherapy in clinical study EMR100070-003 and adverse reactions from a phase&nbsp;I study (EMR100070-001) in solid tumours</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:586px"><thead><tr><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Adverse reactions</p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Lymphopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombocytopenia, eosinophilia<sup>&sect;</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Drug hypersensitivity, hypersensitivity anaphylactic reaction, Type&nbsp;I hypersensitivity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypothyroidism*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Adrenal insufficiency*, hyperthyroidism*, thyroiditis*, autoimmune thyroiditis*, adrenocortical insufficiency acute*, autoimmune hypothyroidism*, hypopituitarism*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Diabetes mellitus*, Type&nbsp;1 diabetes mellitus*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache, dizziness, neuropathy peripheral</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Guillain‑Barr&eacute; Syndrome*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uveitis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Myocarditis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypertension, hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Flushing</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Cough, dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pneumonitis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea, diarrhoea, constipation, vomiting, abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Colitis*, autoimmune colitis*, enterocolitis*, ileus</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pancreatitis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Autoimmune hepatitis*, acute hepatic failure*, hepatic failure*, hepatitis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash*, pruritus*, rash maculo‑papular*, dry skin</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash pruritic*, erythema*, rash generalised*, psoriasis*, rash erythematous*, rash macular*, rash papular*, dermatitis exfoliative*, erythema multiforme*, pemphigoid*, pruritus generalised*, eczema, dermatitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Back pain, arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Myositis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tubulo-interstitial nephritis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administrative site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue, pyrexia, oedema peripheral</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Asthenia, chills, influenza like illness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Systemic inflammatory response syndrome*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Weight decreased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Gamma-glutamyltransferase increased, blood alkaline phosphatase increased, amylase increased, lipase increased, blood creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Alanine aminotransferase (ALT) increased*, aspartate aminotransferase (AST) increased*, blood creatine phosphokinase increased*, transaminases increased*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Infusion related reaction</p></td></tr></tbody></table><p dir="ltr"><sup>*</sup> Immune‑related adverse reaction based on medical review</p><p dir="ltr"><sup>&sect;</sup> Reaction only observed from study EMR 100070-003 (Part B) after the data cut-off of the pooled analysis, hence frequency estimated</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Renal cell carcinoma</u></em></p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">The safety of avelumab in combination with axitinib has been evaluated in 489&nbsp;patients with advanced RCC receiving 10&nbsp;mg/kg avelumab every 2&nbsp;weeks and axitinib 5&nbsp;mg orally twice daily in two clinical studies.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In this patient population, the most common adverse reactions were diarrhoea (62.8%), hypertension (49.3%), fatigue (42.9%), nausea (33.5%), dysphonia (32.7%), decreased appetite (26.0%), hypothyroidism (25.2%), cough (23.7%), headache (21.3%), dyspnoea (20.9%), and arthralgia (20.9%).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tabulated list of adverse reactions</u></p><p dir="ltr">Adverse reactions reported for 489&nbsp;patients with advanced RCC treated in two clinical studies with avelumab in combination with axitinib are presented in Table&nbsp;3.</p><p dir="ltr">&nbsp;</p><p dir="ltr">These reactions are presented by system organ class and frequency. Frequencies are defined as: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;</strong><strong>3: Adverse reactions in patients treated with avelumab in combination with axitinib in clinical studies B9991002 and B9991003</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:605px"><thead><tr><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Adverse reactions</p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash pustular</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaemia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Lymphopenia, eosinophilia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypothyroidism</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperthyroidism, adrenal insufficiency, thyroiditis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Autoimmune thyroiditis, hypophysitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Diabetes mellitus, Type 1 diabetes mellitus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache, dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Neuropathy peripheral</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Myocarditis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension, flushing</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Dysphonia, cough, dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pneumonitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea, nausea, constipation, vomiting, abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dry mouth, colitis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Autoimmune colitis, autoimmune pancreatitis, enterocolitis, ileus, pancreatitis necrotizing</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hepatic function abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hepatitis, hepatotoxicity, immune-mediated hepatitis, liver disorder</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash pruritic, rash maculo-papular, pruritus generalized, dermatitis acneiform, erythema, rash macular, rash papular, rash erythematous, dermatitis, eczema, rash generalized</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Drug eruption, erythema multiforme, psoriasis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Arthralgia, back pain, myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Acute kidney injury</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administrative site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue, chills, asthenia, pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oedema peripheral, influenza like illness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Weight decreased, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Blood creatinine increased, amylase increased, lipase increased, gamma‑glutamyl transferase increased, blood alkaline phosphatase increased, blood creatine phosphokinase increased, blood thyroid stimulating hormone decreased, transaminases increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Liver function test increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Infusion related reaction</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Description of selected adverse reactions</u></p><p dir="ltr">Data for immune‑related adverse reactions for avelumab as a monotherapy are based on 1,650&nbsp;patients in the phase&nbsp;I study EMR100070-001 in solid tumours and 88&nbsp;patients in study EMR100070-003, and for avelumab in combination with axitinib are based on 489&nbsp;patients in study B9991002 and B9991003 (see section&nbsp;5.1).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The management guidelines for these adverse reactions are described in section&nbsp;4.4.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune‑related pneumonitis</u></em></p><p dir="ltr">In patients treated with avelumab as monotherapy, 1.2% (21/1,738) of patients developed immune‑related pneumonitis. Of these patients, there was 1 (0.1%) patient with a fatal outcome, 1&nbsp;(0.1%) patient with Grade&nbsp;4, and 5 (0.3%) patients with Grade&nbsp;3 immune‑related pneumonitis.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of immune‑related pneumonitis was 2.5&nbsp;months (range: 3&nbsp;days to 11&nbsp;months). The median duration was 7&nbsp;weeks (range: 4&nbsp;days to more than 4&nbsp;months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab was discontinued in 0.3% (6/1,738) of patients due to immune-related pneumonitis. All 21&nbsp;patients with immune-related pneumonitis were treated with corticosteroids and 17 (81%) of the 21&nbsp;patients were treated with high‑dose corticosteroids for a median of 8&nbsp;days (range: 1&nbsp;day to 2.3&nbsp;months). Immune‑related pneumonitis resolved in 12 (57%) of the 21&nbsp;patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients treated with avelumab in combination with axitinib, 0.6% (3/489) of patients developed immune‑related pneumonitis. Of these patients, none experienced immune‑related pneumonitis Grade&nbsp;&ge;&nbsp;3.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of immune‑related pneumonitis was 3.7&nbsp;months (range: 2.7&nbsp;months to 8.6&nbsp;months). The median duration was 2.6&nbsp;months (range: 3.3&nbsp;weeks to more than 7.9&nbsp;months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Immune‑related pneumonitis did not lead to discontinuation of avelumab in any patient. All 3&nbsp;patients with immune-related pneumonitis were treated with high‑dose corticosteroids for a median of 3.3&nbsp;months (range: 3&nbsp;weeks to 22.3&nbsp;months). Immune‑related pneumonitis resolved in 2 (66.7%) of the 3&nbsp;patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune‑related hepatitis</u></em></p><p dir="ltr">In patients treated with avelumab as monotherapy, 0.9% (16/1,738) of patients developed immune‑related hepatitis. Of these patients, there were 2 (0.1%) patients with a fatal outcome, and 11&nbsp;(0.6%) patients with Grade&nbsp;3 immune‑related hepatitis<em>.</em></p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of immune‑related hepatitis was 3.2&nbsp;months (range: 1&nbsp;week to 15&nbsp;months). The median duration was 2.5&nbsp;months (range: 1&nbsp;day to more than 7.4&nbsp;months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab was discontinued in 0.5% (9/1,738) of patients due to immune-related hepatitis. All 16&nbsp;patients with immune-related hepatitis treated with corticosteroids and 15 (94%) of the 16&nbsp;patients received high‑dose corticosteroids for a median of 14&nbsp;days (range: 1&nbsp;day to 2.5&nbsp;months). Immune‑related hepatitis resolved in 9 (56%) of the 16&nbsp;patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients treated with avelumab in combination with axitinib, 6.3% (31/489) of patients developed immune‑related hepatitis. Of these patients, there were 18 (3.7%) patients with Grade&nbsp;3 and 3 (0.6%) patients with Grade&nbsp;4 immune‑related hepatitis.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of immune‑related hepatitis was 2.3&nbsp;months (range: 2.1&nbsp;weeks to 14.5&nbsp;months). The median duration was 2.1&nbsp;weeks (range: 2&nbsp;days to 8.9 months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab was discontinued in 4.7% (23/489) of patients due to immune-related hepatitis. All 31&nbsp;patients with immune‑related hepatitis were treated for hepatitis including 30 (96.8%) patients treated with corticosteroids and 1&nbsp;patient with a non-steroidal immunosuppressant. Twenty‑eight (90.3%) of the 31&nbsp;patients received high dose corticosteroids for a median of 2.4&nbsp;weeks (range: 1&nbsp;day to 10.2&nbsp;months). Immune‑related hepatitis resolved in 27 (87.1%) of the 31&nbsp;patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune‑related colitis</u></em></p><p dir="ltr">In patients treated with avelumab as monotherapy, 1.5% (26/1,738) of patients developed immune‑related colitis. Of these patients, there were 7 (0.4%) patients with Grade&nbsp;3 immune‑related colitis.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of immune‑related colitis was 2.1&nbsp;months (range: 2&nbsp;days to 11&nbsp;months). The median duration was 6&nbsp;weeks (range: 1&nbsp;day to more than 14&nbsp;months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab was discontinued in 0.5% (9/1,738) of patients due to immune-related colitis. All 26&nbsp;patients with immune-related colitis were treated with corticosteroids and 15 (58%) of the 26&nbsp;patients received high-dose corticosteroids for a median of 19&nbsp;days (range: 1&nbsp;day to 2.3&nbsp;months). Immune‑related colitis resolved in 18 (70%) of 26&nbsp;patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients treated with avelumab in combination with axitinib, 2.7% (13/489) of patients developed immune‑related colitis. Of these patients, there were 9 (1.8%) patients with Grade&nbsp;3 immune-related colitis.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of immune‑related colitis was 5.1&nbsp;months (range: 2.3&nbsp;weeks to 14&nbsp;months). The median duration was 1.6&nbsp;weeks (range: 1&nbsp;day to more than 9&nbsp;months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab was discontinued in 0.4% (2/489) of patients due to immune-related colitis. All 13&nbsp;patients with immune-related colitis were treated with corticosteroids and 12 (92.3%) of the 13&nbsp;patients received high‑dose corticosteroids for a median of 2.3&nbsp;weeks (range: 5&nbsp;days to 4.6&nbsp;months). Immune‑related colitis resolved in 10 (76.9%) of 13&nbsp;patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune-related pancreatitis</u></em></p><p dir="ltr">In patients treated with avelumab as monotherapy, immune-related pancreatitis occurred in less than 1% (1/4,000) of patients across clinical trials in multiple tumour types and in 0.6% (3/489) of patients receiving avelumab in combination with axitinib including 2 (0.4%) patients with fatal outcome.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune-related myocarditis</u></em></p><p dir="ltr">In patients treated with avelumab as monotherapy, immune-related myocarditis occurred in less than 1% (5/4,000) of patients across clinical trials in multiple tumour types and in 0.6% (3/489) of patients receiving avelumab in combination with axitinib including 2 (0.4%) patients with fatal outcome.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune‑related endocrinopathies</u></em></p><p dir="ltr"><em>Thyroid disorders</em></p><p dir="ltr">In patients treated with avelumab as monotherapy, 6% (98/1,738) of patients developed immune‑related thyroid disorders, including 90 (5%) patients with hypothyroidism, 7 (0.4%) with hyperthyroidism, and 4 (0.2%) with thyroiditis. Of these patients, there were 3 (0.2%) patients with Grade&nbsp;3 immune‑related thyroid disorders.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of thyroid disorders was 2.8&nbsp;months (range: 2&nbsp;weeks to 13&nbsp;months). The median duration was not estimable (range: 1&nbsp;day to more than 26&nbsp;months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab was discontinued in 0.1% (2/1,738) of patients due to immune-related thyroid disorders. Thyroid disorders resolved in 7 (7%) of the 98&nbsp;patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients treated with avelumab in combination with axitinib, 24.7% (121/489) of patients developed immune‑related thyroid disorders, including 111 (22.7%) patients with hypothyroidism, 17 (3.5%) with hyperthyroidism, and 7 (1.4%) with thyroiditis. Of these patients, there were 2 (0.4%) patients with Grade&nbsp;3 immune‑related thyroid disorders.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of thyroid disorders was 2.8&nbsp;months (range: 3.6&nbsp;weeks to 19.3&nbsp;months). The median duration was not estimable (range: 8&nbsp;days to more than 23.9&nbsp;months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab was discontinued in 0.2% (1/489) of patients due to immune-related thyroid disorders. Thyroid disorders resolved in 15 (12.4%) of the 121&nbsp;patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Adrenal insufficiency</em></p><p dir="ltr">In patients treated with avelumab as monotherapy, 0.5% (8/1,738) of patients developed immune‑related adrenal insufficiency. Of these patients, there was 1 (0.1%) patient with Grade&nbsp;3 immune‑related adrenal insufficiency.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of immune‑related adrenal insufficiency was 2.5&nbsp;months (range: 1&nbsp;day to 8&nbsp;months). The median duration was not estimable (range: 2&nbsp;days to more than 6&nbsp;months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab was discontinued in 0.1% (2/1,738) of patients due to immune-related adrenal insufficiency. All 8&nbsp;patients with immune-related adrenal insufficiency were treated with corticosteroids, 4 (50%) of the 8&nbsp;patients received high‑dose systemic corticosteroids (&ge;&nbsp;40&nbsp;mg prednisone or equivalent) followed by a taper for a median of 1&nbsp;day (range: 1&nbsp;day to 24&nbsp;days). Adrenal insufficiency resolved in 1&nbsp;patient with corticoid treatment at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients treated with avelumab in combination with axitinib, 1.8% (9/489) of patients developed immune-related adrenal insufficiency. Of these patients, there were 2 (0.4%) patients with Grade&nbsp;3 immune‑related adrenal insufficiency.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of immune‑related adrenal insufficiency was 5.5&nbsp;months (range: 3.6&nbsp;weeks to 8.7&nbsp;months). The median duration was 2.8&nbsp;months (range: 3&nbsp;days to more than 15.5&nbsp;months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Immune-related adrenal insufficiency did not lead to discontinuation of avelumab in any patient. Eight (88.9%) patients with immune-related adrenal insufficiency were treated with corticosteroids and 2 (25%) of the 8&nbsp;patients received high‑dose corticosteroids (&ge;&nbsp;40&nbsp;mg prednisone or equivalent) for a median of 8&nbsp;days (range: 5&nbsp;days to 11&nbsp;days). Adrenal insufficiency resolved in 4 (44.4%) of the 9&nbsp;patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Type&nbsp;1 diabetes mellitus</em></p><p dir="ltr">In patients treated with avelumab as monotherapy, Type&nbsp;1 diabetes mellitus without an alternative aetiology occurred in 0.1% (2/1,738) of patients including two Grade&nbsp;3 reactions that led to permanent discontinuation of avelumab.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients treated with avelumab in combination with axitinib, Type&nbsp;1 diabetes mellitus without an alternative aetiology occurred in 1.0% (5/489) of patients. Of these patients, there was 1 (0.2%) patient with Grade&nbsp;3 Type&nbsp;1 diabetes mellitus.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of Type&nbsp;1 diabetes mellitus was 1.9&nbsp;months (range: 1.1&nbsp;months to 7.3&nbsp;months).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab was discontinued in 0.2% (1/489) of patients due to Type&nbsp;1 diabetes mellitus. All 5&nbsp;patients with Type&nbsp;1 diabetes mellitus were treated with insulin. Type&nbsp;1 diabetes mellitus did not resolve in any of the patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immune-related nephritis and renal dysfunction</u></em></p><p dir="ltr">In patients treated with avelumab as monotherapy, immune-related nephritis occurred in 0.1% (1/1,738) of patients receiving avelumab leading to permanent discontinuation of avelumab.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients treated with avelumab in combination with axitinib, immune-related nephritis occurred in 0.4% (2/489) of patients. Of these patients, there were 2 (0.4%) patients with Grade&nbsp;3 immune-related nephritis.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of immune-related nephritis was 1.2&nbsp;months (range: 2.9&nbsp;weeks to 1.8&nbsp;months). The median duration was 1.3&nbsp;weeks (range: more than 4&nbsp;days to 1.3&nbsp;weeks).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Immune-related nephritis did not lead to discontinuation of avelumab in any patient. All 2&nbsp;patients with immune-related nephritis were treated with high‑dose corticosteroids for a median of 1.1&nbsp;weeks (range: 3&nbsp;days to 1.9&nbsp;weeks). Immune-related nephritis resolved in 1 (50%) of the 2&nbsp;patients at the time of data cut‑off.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Hepatotoxicity (in combination with axitinib)</u></em></p><p dir="ltr">In patients treated with avelumab in combination with axitinib, Grades&nbsp;3 and Grade&nbsp;4 increased ALT and increased AST were reported in 9% and 7% of patients, respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients with ALT&nbsp;&ge;&nbsp;3 times ULN (Grades&nbsp;2-4, n=82), ALT resolved to Grades&nbsp;0-1 in 92%.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Among the 73&nbsp;patients who were rechallenged with either avelumab (59%) or axitinib (85%) monotherapy or with both (55%), 66% had no recurrence of ALT&nbsp;&ge;&nbsp;3 times ULN.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Immunogenicity</u></em></p><p dir="ltr">Of 1,738&nbsp;patients treated with avelumab 10&nbsp;mg/kg as an intravenous infusion every 2&nbsp;weeks, 1,627&nbsp;were evaluable for treatment-emergent anti-drug antibodies (ADA) and 96 (5.9%) tested positive. In ADA positive patients, there may be an increased risk for infusion‑related reactions (about 40% and 25% in ADA ever‑positive and ADA never‑positive patients, respectively). Based on data available, including the low incidence of immunogenicity, the impact of ADA on pharmacokinetics, efficacy and safety is uncertain, while the impact of neutralizing antibodies (nAb) is unknown.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Of the 480&nbsp;patients with at least one valid ADA result at any time point treated with avelumab 10&nbsp;mg/kg as an intravenous infusion every 2&nbsp;weeks in combination with axitinib 5&nbsp;mg twice daily, 453 were evaluable for treatment-emergent ADA and 66 (14.6%) tested positive. A new ADA method with improved sensitivity and drug tolerance was used in the RCC population. Overall, there was no evidence of altered pharmacokinetic profile, increased incidence of infusion reactions or effects on efficacy with anti-avelumab antibody development.</p><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>Toll free phone: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Three patients were reported to be overdosed with 5% to 10% above the recommended dose of avelumab. The patients had no symptoms, did not require any treatment for the overdose, and continued on avelumab therapy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions. The treatment is directed to the management of symptoms.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Other antineoplastic agents, monoclonal antibodies, ATC code: L01XC31.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against programmed death ligand&nbsp;1 (PD‑L1). Avelumab binds PD‑L1 and blocks the interaction between PD‑L1 and the programmed death&nbsp;1 (PD‑1) and B7.1 receptor. This removes the suppressive effects of PD‑L1 on cytotoxic CD8<sup>+</sup> T‑cells, resulting in the restoration of anti‑tumour T‑cell responses.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab has also shown to induce natural killer (NK) cell‑mediated direct tumour cell lysis via antibody‑dependent cell‑mediated cytotoxicity (ADCC).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Clinical efficacy and safety</u></p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr"><em><u>Merkel cell carcinoma (study</u></em><em><u> </u></em><em><u>EMR100070-</u></em><em><u>003)</u></em></p><p dir="ltr">The efficacy and safety of avelumab was investigated in the study EMR100070-003 with two parts. Part&nbsp;A was a single‑arm, multi-centre study conducted in patients with histologically confirmed metastatic MCC, whose disease had progressed on or after chemotherapy administered for distant metastatic disease, with a life expectancy of more than 3&nbsp;months. Part&nbsp;B included patients with histologically confirmed metastatic MCC who were treatment-na&iuml;ve to systemic therapy in the metastatic setting.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients with active or a history of central nervous system (CNS) metastasis; active or a history of autoimmune disease; a history of other malignancies within the last 5&nbsp;years; organ transplant; conditions requiring therapeutic immune suppression or active infection with HIV, or hepatitis B or C were excluded.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients received avelumab at a dose of 10&nbsp;mg/kg every 2&nbsp;weeks until disease progression or unacceptable toxicity. Patients with radiological disease progression not associated with significant clinical deterioration, defined as no new or worsening symptoms, no change in performance status for greater than two weeks, and no need for salvage therapy could continue treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Tumour response assessments were performed every 6&nbsp;weeks, as assessed by an Independent Endpoint Review Committee (IERC) using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For Part&nbsp;A, the major efficacy outcome measure was confirmed best overall response (BOR); secondary efficacy outcome measures included duration of response (DOR), and progression‑free survival (PFS).</p><p dir="ltr">&nbsp;</p><p dir="ltr">For Part&nbsp;A, an efficacy analysis was conducted in all 88&nbsp;patients after a minimum follow-up of 36&nbsp;months. Patients received a median of 7&nbsp;doses of avelumab (range: 1&nbsp;dose to 95&nbsp;doses), and the median duration of treatment was 17&nbsp;weeks (range: 2&nbsp;weeks to 208&nbsp;weeks).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Of the 88&nbsp;patients, 65 (74%) were male, the median age was 73&nbsp;years (range 33&nbsp;years to 88&nbsp;years), 81&nbsp;(92%) patients were Caucasian, and 49 (56%) patients and 39 (44%) patients with an Eastern Cooperative Oncology Group (ECOG) performance status 0 and&nbsp;1, respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Overall, 52 (59%) patients were reported to have had 1&nbsp;prior anti‑cancer therapy for MCC, 26 (30%) with 2&nbsp;prior therapies, and 10 (11%) with 3 or more prior therapies. Forty‑seven (53%) of the patients had visceral metastases.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table&nbsp;4 summarises efficacy endpoints in patients receiving avelumab at the recommended dose for study EMR100070-003, Part&nbsp;A, with a minimum follow-up of 36&nbsp;months.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;</strong><strong>4: Response to avelumab 10&nbsp;mg/kg every 2&nbsp;weeks in patients with metastatic MCC in study EMR100070-003 (Part&nbsp;A) *</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:495px"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy endpoints (Part&nbsp;A)</strong></p><p><strong>(per RECIST v1.1, IERC)</strong></p></td><td style="vertical-align:top"><p><strong>Results</strong></p><p><strong>(N=88)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate (ORR)</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Response rate, CR+PR** n (%)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>29 (33.0%)</p><p>(23.3, 43.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Confirmed best overall response (BOR)</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete response (CR)** n (%)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Partial response (PR)** n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>10 (11.4%)</p><p>19 (21.6%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response (DOR)</strong><sup>a</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median, months</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Minimum, maximum (months)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;6&nbsp;months by K‑M, (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;12&nbsp;months by K‑M, (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;24&nbsp;months by K‑M, (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;36&nbsp;months by K‑M, (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>40.5</p><p>(18, not estimable)</p><p>2.8, 41.5+</p><p>93% (75, 98)</p><p>71% (51, 85)</p><p>67% (47, 82)</p><p>52% (26, 73)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Progression‑free survival (PFS)</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median PFS, months</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6‑month PFS rate by K‑M, (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12‑month PFS rate by K‑M, (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24‑month PFS rate by K‑M, (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36‑month PFS rate by K‑M, (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.7</p><p>(1.4, 6.9)</p><p>40% (29, 50)</p><p>29% (19, 39)</p><p>26% (17, 36)</p><p>21% (12, 32)</p></td></tr></tbody></table><p dir="ltr">CI: Confidence interval; RECIST: Response Evaluation Criteria in Solid Tumours; IERC: Independent Endpoint Review Committee; K‑M: Kaplan‑Meier; +denotes a censored value</p><p dir="ltr">* Efficacy data with a minimum follow-up of 36&nbsp;months (cut-off date 14&nbsp;September&nbsp;2018)</p><p dir="ltr">** CR or PR was confirmed at a subsequent tumour assessment</p><p dir="ltr"><sup>a</sup> Based-on number of patients with confirmed response (CR or PR)</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to response was 6&nbsp;weeks (range: 6&nbsp;weeks to 36&nbsp;weeks) after the first dose of avelumab. Twenty‑two out of 29 (76%) patients with response were reported to have responded within 7&nbsp;weeks after the first dose of avelumab.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The Kaplan‑Meier curve of PFS of the 88&nbsp;patients (Part&nbsp;A) with metastatic MCC is presented in Figure&nbsp;1.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure&nbsp;</strong><strong>1: Kaplan‑Meier estimates of progression‑free survival (PFS) per RECIST v1.1, IERC (Part&nbsp;A</strong><strong>, minimum follow-up of 36&nbsp;months</strong><strong>)</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Tumour samples were evaluated for PD-L1 tumour cell expression, and for Merkel cell polyomavirus (MCV) using an investigational immunohistochemistry (IHC) assay. Table&nbsp;5 summarises the PD-L1 expression and MCV status of patients with metastatic MCC in study EMR100070-003 (Part&nbsp;A).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;</strong><strong>5: Objective response rates by PD-L1 expression and MCV tumour status in patients with metastatic MCC in study EMR100070-003 (Part&nbsp;A)</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:479px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Avelumab</strong></p><p><strong>ORR (95% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>PD-L1 expression at cut-off of 1%</strong></p></td><td style="vertical-align:top"><p>N=74<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Positive (n=58)</p></td><td style="vertical-align:top"><p>36.2% (24.0, 49.9)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Negative (n=16)</p></td><td style="vertical-align:top"><p>18.8% (4.0, 45.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PD-L1 expression at cut-off of 5%</strong></p></td><td style="vertical-align:top"><p>N=74<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Positive (n=19)</p></td><td style="vertical-align:top"><p>57.9% (33.5, 79.7)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Negative (n=55)</p></td><td style="vertical-align:top"><p>23.6% (13.2, 37.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>IHC-MCV tumour status</strong></p></td><td style="vertical-align:top"><p>N=77<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Positive (n=46)</p></td><td style="vertical-align:top"><p>28.3% (16.0, 43.5)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Negative (n=31)</p></td><td style="vertical-align:top"><p>35.5% (19.2, 54.6)</p></td></tr></tbody></table><p dir="ltr">IHC: Immunohistochemistry; MCV: Merkel cell polyomavirus; ORR: objective response rate</p><p dir="ltr"><sup>a</sup> Based on data from patients evaluable for PD-L1</p><p dir="ltr"><sup>b</sup> Based on data from patients evaluable for MCV by immunohistochemistry (IHC)</p><p dir="ltr">&nbsp;</p><p dir="ltr">The clinical utility of PD‑L1 as a predictive biomarker in MCC has not been established.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For Part&nbsp;B, the major efficacy outcome measure was durable response, defined as objective response (complete response (CR) or partial response (PR)) with a duration of at least 6&nbsp;months; secondary outcome measures included BOR, DOR, PFS, and OS.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The prespecified interim analysis for Part&nbsp;B included 39&nbsp;patients who received at least one dose of avelumab and 29&nbsp;patients with a minimum 13&nbsp;weeks of follow-up at the time of the data cut‑off (cut‑off date 24&nbsp;March&nbsp;2017).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Of the 39&nbsp;patients, 30 (77%) were male, the median age was 75&nbsp;years (range: 47 to 88&nbsp;years), 33 (85%) were Caucasian, and 31 (79%) and 8 (21%) had an ECOG performance status of 0 and 1 respectively. The efficacy endpoints were based on 29&nbsp;patients with 13&nbsp;weeks of follow-up. The objective response rate (ORR) was 62.1% (95% CI: 42.3, 79.3) with 4 (14%) of patients reported to have a complete response and 14 (48%) to have a partial response. The median duration of response was not estimable (95% CI: 4&nbsp;months, not estimable) with a minimum of 1.2&nbsp;months to a maximum of 8.3&nbsp;months duration. Analysis of progression-free survival (PFS) was based on 39&nbsp;patients who received at least one dose of avelumab, with median PFS of 9.1&nbsp;months (95% CI: 1.9, not estimable) and estimated 3‑month PFS rate by Kaplan-Meier of 67% (95% CI: 48, 80).</p><p dir="ltr">&nbsp;</p><p dir="ltr">After Part&nbsp;B was fully enrolled, a subsequent interim analysis was conducted with 116&nbsp;patients who received at least one dose of avelumab and with at least 7&nbsp;months of follow-up at the time of the data cut‑off (cut‑off date 14&nbsp;September&nbsp;2018). Of the 116&nbsp;patients, 81 (70%) were male, the median age was 74&nbsp;years (range: 41 to 93&nbsp;years), 75 (65%) were Caucasian, and 72 (62%) and 44 (38%) had an ECOG performance status of 0 and 1, respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table&nbsp;6 summarises the subsequent interim analysis of efficacy endpoints including an estimate of the 6‑month rates by Kaplan-Meier for DOR and PFS, in patients receiving avelumab at the recommended dose for study EMR100070-003, Part&nbsp;B.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;</strong><strong>6: Subsequent interim analysis of response to avelumab 10&nbsp;mg/kg every 2&nbsp;weeks in patients with metastatic MCC in study EMR100070-003 (Part&nbsp;B)*</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:471px"><thead><tr><td style="vertical-align:top"><p><strong>Efficacy endpoints (Part&nbsp;B)</strong></p><p><strong>(per RECIST v1.1, IERC)</strong></p></td><td style="vertical-align:top"><p><strong>Results</strong></p><p><strong>(N=116)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Objective response rate (ORR)</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Response rate, CR+PR** n (%)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>46 (39.7%)</p><p>(30.7, 49.2)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Confirmed best overall response (BOR)</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete response (CR)** n (%)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Partial response (PR)** n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16 (13.8%)</p><p>30 (25.9%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response (DOR)</strong><sup>a</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median, months</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Minimum, maximum (months)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;3&nbsp;months by K‑M, (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;6&nbsp;months by K‑M, (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;12&nbsp;months by K‑M, (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>15.2</p><p>(10.2, not estimable)</p><p>1.2, 22.1</p><p>89% (75, 95)</p><p>78% (62, 87)</p><p>60% (40, 75)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Progression‑free survival (PFS)</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median PFS, months</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3‑month PFS rate by K‑M, (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6‑month PFS rate by K‑M, (95% CI)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12‑month PFS rate by K‑M, (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.1</p><p>(1.4, 6.1)</p><p>51% (42, 60)</p><p>41% (32, 50)</p><p>29% (21, 38)</p></td></tr></tbody></table><p dir="ltr">CI: Confidence interval; RECIST: Response Evaluation Criteria in Solid Tumours; IERC: Independent Endpoint Review Committee; K‑M: Kaplan‑Meier</p><p dir="ltr">* Efficacy data with a minimum follow‑up of 7&nbsp;months (cut-off date 14&nbsp;September&nbsp;2018)</p><p dir="ltr">** CR or PR was confirmed at a subsequent tumour assessment</p><p dir="ltr"><sup>a</sup> Based on number of patients with confirmed response (CR or PR)</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure&nbsp;2 presents the Kaplan-Meier curve for PFS from the subsequent interim analysis with 116&nbsp;patients enrolled into Part&nbsp;B with a minimum follow‑up of 7&nbsp;months.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure&nbsp;</strong><strong>2: Kaplan‑Meier estimates of progression‑free survival (PFS) per RECIST v1.1, IERC (Part&nbsp;B, N=116)</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Renal cell carcinoma (study</u></em><em><u> </u></em><em><u>B9991003</u></em><em><u>)</u></em></p><p dir="ltr">The efficacy and safety of avelumab in combination with axitinib was demonstrated in study B9991003, a randomised, multicentre, open-label study of avelumab in combination with axitinib in 886&nbsp;patients with untreated advanced or metastatic RCC with a clear-cell component.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients were included irrespective of prognostic risk groups or tumour PD‑L1 expression and had to have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumours (RECIST) version&nbsp;1.1 that was not been previously irradiated. Patients with prior systemic therapy directed at advanced or metastatic RCC; prior systemic immunotherapy treatment with IL-2, IFN-&alpha;, anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies, or active brain metastasis; active autoimmune disease that might deteriorate when receiving an immunostimulatory agents; a history of other malignancies within the last 5&nbsp;years; organ transplant were ineligible.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Randomization was stratified according to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (0 vs. 1) and region (United States vs. Canada/Western Europe vs. the rest of the world). Patients were randomised (1:1) to one of the following treatment arms:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avelumab 10&nbsp;mg/kg intravenous infusion every 2&nbsp;weeks in combination with axitinib 5&nbsp;mg twice daily orally (N=442). Patients who tolerated axitinib 5&nbsp;mg twice daily without Grade&nbsp;2 or greater axitinib-related adverse events for 2&nbsp;consecutive weeks could increase to 7&nbsp;mg and then subsequently to 10&nbsp;mg twice daily. Axitinib could be interrupted or reduced to 3&nbsp;mg twice daily and subsequently to 2&nbsp;mg twice daily to manage toxicity.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sunitinib 50&nbsp;mg once daily orally for 4&nbsp;weeks followed by 2&nbsp;weeks off (N=444) until radiographic or clinical progression or unacceptable toxicity.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with avelumab and axitinib continued until RECIST v1.1‑defined progression of disease by Blinded Independent Central Review (BICR) assessment or unacceptable toxicity. Administration of avelumab and axitinib was permitted beyond RECIST‑defined disease progression based on investigator&rsquo;s assessment of the patient&rsquo;s benefit-risk and clinical condition, including performance status, clinical symptoms, adverse events and laboratory data. The majority (n=160, 71.4%) of the patients with progressive disease continued treatment with both medicinal products after progression. Assessment of tumour status was performed at baseline, after randomisation at 6&nbsp;weeks, then every 6&nbsp;weeks thereafter up to 18&nbsp;months after randomisation, and every 12&nbsp;weeks thereafter until documented confirmed disease progression by BICR.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The primary efficacy endpoints were progression-free survival (PFS), as assessed by BICR using RECIST v1.1 and overall survival (OS) in the first-line treatment of patients with advanced RCC who have PD‑L1-positive tumours (PD‑L1 expression level &sup3;&nbsp;1%). The key secondary endpoints were PFS based on BICR assessment per RECIST v1.1 and OS irrespective of PD‑L1 expression. PD-L1 status was determined by immunohistochemistry. Additional secondary endpoints included objective response (OR), time to response (TTR) and duration of response (DOR).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The study population characteristics were: median age of 61&nbsp;years (range: 27.0 to 88.0), 38% of patients were 65&nbsp;years or older, 75% were male, 75% were White, and the ECOG performance score was 0 (63%) or 1 (37%).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patient distribution by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups was 21% favourable, 62% intermediate, and 16% poor. Patient distribution by Memorial Sloan&ndash;Kettering Cancer Centre (MSKCC) risk groups was 22% favourable, 65% intermediate, and 11% poor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Efficacy results are presented in Table&nbsp;7 and Figure&nbsp;3 based on a data cut‑off date of 28&nbsp;January&nbsp;2019. With a median OS follow‑up of 19&nbsp;months, OS data were immature with 27% deaths. The observed hazard ratio (HR) for OS was 0.80 (95% CI: 0.616, 1.027) for avelumab in combination with axitinib compared to sunitinib.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Table&nbsp;</strong><strong>7: Efficacy results from study B9991003 in patients irrespective of PD‑L1 expression</strong></p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Efficacy endpoints</strong></p><p><strong>(Based on BICR assessment)</strong></p></td><td style="vertical-align:top"><p><strong>Avelumab plus axitinib</strong></p><p>(N=442)</p></td><td style="vertical-align:top"><p><strong>Sunitinib</strong></p><p>(N=444)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Progression-free survival (PFS)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Events (%)</p></td><td style="vertical-align:top"><p>229 (52)</p></td><td style="vertical-align:top"><p>258 (58)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median in months (95% CI)</p></td><td style="vertical-align:top"><p>13.3 (11.1, 15.3)</p></td><td style="vertical-align:top"><p>8.0 (6.7, 9.8)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.69 (0.574, 0.825)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value*</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12‑month PFS rate by K‑M, (95% CI)**</p></td><td style="vertical-align:top"><p>52.4% (47.4, 57.2)</p></td><td style="vertical-align:top"><p>39.2% (34.1, 44.2)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18‑month PFS rate by K‑M, (95% CI)**</p></td><td style="vertical-align:top"><p>43.9% (38.8, 49.0)</p></td><td style="vertical-align:top"><p>29.3% (24.2, 34.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Confirmed objective response rate (ORR)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Objective response rate (ORR) n (%)</p></td><td style="vertical-align:top"><p>232 (52.5)</p></td><td style="vertical-align:top"><p>121 (27.3)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>47.7, 57.2</p></td><td style="vertical-align:top"><p>23.2, 31.6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete response (CR) n (%)</p></td><td style="vertical-align:top"><p>17 (3.8)</p></td><td style="vertical-align:top"><p>9 (2.0)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Partial response (PR) n (%)</p></td><td style="vertical-align:top"><p>215 (48.6)</p></td><td style="vertical-align:top"><p>112 (25.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Time to response (TTR)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median, months (range)</p></td><td style="vertical-align:top"><p>2.7 (1.2, 20.7)</p></td><td style="vertical-align:top"><p>4.0 (1.2, 18.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response (DOR)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median, months (95% CI)</p></td><td style="vertical-align:top"><p>18.5 (17.8, NE)</p></td><td style="vertical-align:top"><p>NE (16.4, NE)</p></td></tr></tbody></table><p dir="ltr">BICR: Blinded Independent Central Review; CI: Confidence interval; NE: Not estimable.</p><p dir="ltr">* 1‑sided p-value based on stratified log-rank.</p><p dir="ltr">** CIs are derived using the log-log transformation with back transformation to untransformed scale.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure&nbsp;</strong><strong>3: Kaplan‑Meier estimates for progression-free survival based on BICR assessment in patients irrespective of PD‑L1 expression</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Improvement of PFS was observed across pre‑specified subgroups.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Figure</strong><strong>&nbsp;4: Forest plot of progression‑free survival based on BICR assessment in patients irrespective of PD‑L1 expression</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population</u></p><p dir="ltr">The European Medicines Agency has waived the obligation to submit the results of studies with Bavencio in all subsets of the paediatric population for the treatment of Merkel cell carcinoma and renal cell carcinoma (see section&nbsp;4.2 for information on paediatric use).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Conditional approval</u></p><p dir="ltr">This medicinal product has been authorised under a so-called &lsquo;conditional approval&rsquo; scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Avelumab pharmacokinetics (PK) was assessed using a population PK approach for avelumab as monotherapy and avelumab in combination with axitinib.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Based on a population PK analysis for avelumab as monotherapy and in combination with axitinib, there are no expected clinically meaningful differences in exposure of avelumab between settings administered every 2&nbsp;weeks at 800&nbsp;mg or 10&nbsp;mg/kg.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">Avelumab is expected to be distributed in the systemic circulation and to a lesser extent in the extracellular space. The volume of distribution at steady state was 4.72&nbsp;L.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Consistent with a limited extravascular distribution, the volume of distribution of avelumab at steady state is small. As expected for an antibody, avelumab does not bind to plasma proteins in a specific manner.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">Based on a population pharmacokinetic analysis from 1,629&nbsp;patients, the value of total systemic clearance (CL) is 0.59&nbsp;L/day. In the supplemental analysis, avelumab CL was found to decrease over time: the largest mean maximal reduction (% coefficient of variation [CV%]) from baseline value with different tumour types was approximately 32.1% (CV&nbsp;36.2%).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Steady‑state concentrations of avelumab were reached after approximately 4 to 6&nbsp;weeks (2 to 3&nbsp;cycles) of repeated dosing at 10&nbsp;mg/kg every 2&nbsp;weeks, and systemic accumulation was approximately 1.25‑fold.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The elimination half‑life (t<sub>&frac12;</sub>) at the recommended dose is 6.1&nbsp;days based on the population PK analysis.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Linearity/non‑linearity</u></p><p dir="ltr">The exposure of avelumab increased dose‑proportionally in the dose range of 10&nbsp;mg/kg to 20&nbsp;mg/kg every 2&nbsp;weeks.</p><p dir="ltr">&nbsp;</p><p dir="ltr">When avelumab 10&nbsp;mg/kg was administered in combination with axitinib 5&nbsp;mg, the respective exposures of avelumab and axitinib were unchanged compared to the single agents. There was no evidence to suggest a clinically relevant change of avelumab clearance over time in patients with advanced RCC.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Special populations</u></p><p dir="ltr">A population pharmacokinetic analysis suggested no difference in the total systemic clearance of avelumab based on age, gender, race, PD‑L1 status, tumour burden, renal impairment and mild or moderate hepatic impairment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Total systemic clearance increases with body weight. Steady-state exposure was approximately uniform over a wide range of body weights (30 to 204&nbsp;kg) for body weight normalised dosing.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Renal impairment</u></em></p><p dir="ltr">No clinically important differences in the clearance of avelumab were found between patients with mild (glomerular filtration rate (GFR) 60 to&nbsp;89&nbsp;mL/min, Cockcroft-Gault Creatinine Clearance (CrCL); n=623), moderate (GFR 30 to 59&nbsp;mL/min, n=320) and patients with normal (GFR &ge;&nbsp;90&nbsp;mL/min, n=671) renal function.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab has not been studied in patients with severe renal impairment (GFR 15 to 29&nbsp;mL/min).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Hepatic impairment</u></em></p><p dir="ltr">No clinically important differences in the clearance of avelumab were found between patients with mild hepatic impairment (bilirubin &le;&nbsp;ULN and AST &gt;&nbsp;ULN or bilirubin between 1 and 1.5&nbsp;times ULN, n=217) and normal hepatic function (bilirubin and AST &le;&nbsp;ULN, n=1,388) in a population PK analysis. Hepatic impairment was defined by National Cancer Institute (NCI) criteria of hepatic dysfunction.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Avelumab has not been studied in patients with moderate hepatic impairment (bilirubin between 1.5 and 3&nbsp;times ULN) or severe hepatic impairment (bilirubin &gt;&nbsp;3&nbsp;times<strong> </strong>ULN).</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Non‑clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity in Cynomolgus monkeys administered intravenously doses of 20, 60 or 140&nbsp;mg/kg once a week for1&nbsp;month and 3&nbsp;months, followed by a 2-month recovery period after the 3‑month dosing period. Perivascular mononuclear cell cuffing was observed in the brain and spinal cord of monkeys treated with avelumab at &ge;&nbsp;20&nbsp;mg/kg for 3&nbsp;months. Although there was no clear dose-response relationship, it cannot be excluded that this finding was related to avelumab treatment.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Animal reproduction studies have not been conducted with avelumab. The PD‑1/PD‑L1 pathway is thought to be involved in maintaining tolerance to the foetus throughout pregnancy. Blockade of PD‑L1 signalling has been shown in murine models of pregnancy to disrupt tolerance to the foetus and to result in an increase in foetal loss. These results indicate a potential risk that administration of avelumab during pregnancy could cause foetal harm, including increased rates of abortion or stillbirth.</p><p dir="ltr">&nbsp;</p><p dir="ltr">No studies have been conducted to assess the potential of avelumab for carcinogenicity or genotoxicity.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Fertility studies have not been conducted with avelumab. In 1‑month and 3‑month repeat‑dose toxicology studies in monkeys, there were no notable effects in the female reproductive organs. Many of the male monkeys used in these studies were sexually immature and thus no explicit conclusions regarding effects on male reproductive organs can be made.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol 510 mg</p><p>Glacial acetic acid 6 mg</p><p>Polysorbate&nbsp;(20) 5 mg</p><p>Sodium hydroxide 3 mg</p><p>Water for injections 10 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">This medicinal product must not be mixed with other medicinal products except those mentioned in section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
2 years

After opening
From a microbiological point of view, once opened, the medicinal product should be diluted and infused immediately.

After preparation of infusion
Chemical and physical in use stability of the diluted solution has been demonstrated for 24 hours at 20°C to 25°C and room light. From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the diluted solution should be infused immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

Protect from light. Store diluted BAVENCIO solution: At room temperature up to 25°C for no more than 4 hours from the time of dilution. Or, under refrigeration at 2°C to 8°C for no more than 24 hours from the time of dilution. If refrigerated, allow the diluted solution to come to room temperature prior to administration. Do not freeze or shake
diluted solution”.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store in a refrigerator (2&deg;C&nbsp;‑&nbsp;8&deg;C).</p><p dir="ltr">Do not freeze.</p><p dir="ltr">Store in the original package in order to protect from light.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For storage conditions after dilution of the medicinal product, see section&nbsp;6.3.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">10&nbsp;mL of concentrate in a vial (Type&nbsp;I glass) with a halobutyl rubber stopper and an aluminium seal fitted with a removable plastic cap.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pack size of 1&nbsp;vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Bavencio is compatible with polyethylene, polypropylene, and ethylene vinyl acetate infusion bags, glass bottles, polyvinyl chloride infusion sets and in‑line filters with polyethersulfone membranes with pore sizes of 0.2&nbsp;micrometre.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Handling instructions</u></p><p dir="ltr">An aseptic technique for the preparation of the solution for infusion should be used.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The vial should be visually inspected for particulate matter and discoloration. Bavencio is a clear, colourless to slightly yellow solution. If the solution is cloudy, discoloured, or contains particulate matters, the vial should be discarded.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An infusion bag of appropriate size (preferably 250&nbsp;mL) containing either sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection or with sodium chloride 4.5&nbsp;mg/mL (0.45%) solution for injection should be used. The required volume of Bavencio should be withdrawn from the vial(s) and transferred to the infusion bag. Any partially used or empty vials have to be discarded.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The diluted solution should be mixed by gently inverting the bag in order to avoid foaming or excessive shearing of the solution.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solution should be inspected to ensure it is clear, colourless, and free of visible particles. The diluted solution should be used immediately once prepared.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not co‑administer other medicinal products through the same intravenous line. Administer the solution for infusion using a sterile, non‑pyrogenic, low‑protein binding 0.2&nbsp;micrometre in‑line or add‑on filter as described in section&nbsp;4.2.</p><p dir="ltr">&nbsp;</p><p dir="ltr">After administration of Bavencio, the line should be flushed with either sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection or with sodium chloride 4.5&nbsp;mg/mL (0.45%) solution for injection.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not freeze or shake the diluted solution. If refrigerated, allow the diluted solution in the intravenous bags to come to room temperature prior to use.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Disposal</u></p><p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Merck Europe B.V.
Gustav Mahlerplein 102
1082 MA Amsterdam
The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01 July 2021  
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>